The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serum multiplex analysis of checkpoint proteins in association with immune-related adverse events in patients with melanoma receiving adjuvant anti-PD-1 therapy.
 
Andrew David Knight
No Relationships to Disclose
 
Sabrina Bruno
Stock and Other Ownership Interests - Moderna Therapeutics
 
Caroline Jane Layding
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Cindy Sander
No Relationships to Disclose
 
Walter J Storkus
No Relationships to Disclose
 
Lilit Karapetyan
No Relationships to Disclose
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Bristol Myers Squibb; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; CytomX Therapeutics; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lytix Biopharma; Magnolia Innovation; Merck; Natera; Novartis; OncoCyte; OncoSec; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda; Valar Labs
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron